Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 3

OSCIENT PHARMACEUTICALS CORP

Form 3

December 03, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement OSCIENT PHARMACEUTICALS CORP [OSCI] À DellaCamera Capital (Month/Day/Year) Management, LLC 11/25/2008 (Last) (First) (Middle) 5. If Amendment, Date Original 4. Relationship of Reporting Person(s) to Issuer Filed(Month/Day/Year) 461 FIFTH AVENUE, 10TH (Check all applicable) **FLOOR** (Street) 6. Individual or Joint/Group Director __X__ 10% Owner Officer Other Filing(Check Applicable Line) (give title below) (specify below) _X_ Form filed by One Reporting Person NEW YORK. NYÂ 10017 _ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security 2. Amount of Securities 3. 4. Nature of Indirect Beneficial Beneficially Owned Ownership (Instr. 4) Ownership (Instr. 5) (Instr. 4) Form: Direct (D) or Indirect (I) (Instr. 5) $D^{(1)(2)(3)}$ Â Common Stock 1,647,400

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		(1115u. 4 <i>)</i>	Derivative	Security:	

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 3

Date **Expiration Title** Direct (D) Amount or Security Exercisable Date Number of or Indirect Shares (I) (Instr. 5) 12.50% Convertible

Common \$ 1.1 (5) Guaranteed Senior Notes $\hat{A}^{(4)}$ $\hat{A}^{(4)}$ 5,990,000 $D^{(1)(2)(3)} \hat{A}$ Stock

due 2011

Reporting Owners

Relationships Reporting Owner Name / Address

Director 10% Owner Officer Other

DellaCamera Capital Management, LLC **461 FIFTH AVENUE** 10TH FLOOR NEW YORK, NYÂ 10017

Â ÂΧ Â Â

Signatures

Ralph DellaCamera, Jr., Managing 12/03/2008 Member

> **Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects the securities of the issuer owned directly by DellaCamera Capital Master Fund, Ltd. (the "Master Fund").
- DellaCamera Capital Management, LLC ("DCM") acts as the investment manager of the Master Fund. DellaCamera Capital Fund, Ltd. (the "Offshore Fund") is the controlling shareholder of the Master Fund. Ralph DellaCamera, Jr., Andrew Kurtz and Vincent Spinnato are the controlling persons of DCM (collectively, Messrs. DellaCamera, Kurtz and Spinnato shall be referred to as the "Controlling Persons").
- DCM, the Offshore Fund and each Controlling Person may each be deemed to indirectly beneficially own the securities reported herein (3) held by the Master Fund. For purposes of this Form 3, DCM, the Offshore Fund and each Controlling Person each disclaims ownership of the securities reported herein owned by the Master Fund, except to the extent of their pecuniary interest therein.
- The issuer's 12.50% Convertible Guaranteed Senior Notes due 2011 (the "Notes") are immediately convertible into shares of common stock. These Notes mature on January 15, 2011, unless earlier converted or repurchased.
- The initial conversion rate of the Notes is 909.0909 shares per \$1,000 principal amount of Notes (equal to a conversion price of approximately \$1.10 per share).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2